• If you are wondering whether Medtronic stock is attractively priced or just looks cheap after a rough patch, the recent valuation picture gives you a lot to weigh up.
• The share price closed at US$76.15 and has declined 11.6% over the past month, 20.7% year to date, and 9.1% over the last 12 months, which will catch the eye of anyone watching for changes in risk or potential upside.
• Recent coverage around Medtronic has focused on its position as a large medical equipment company at a time when investors are reassessing established healthcare stocks more broadly. This backdrop helps explain why the share price has been under pressure even as some investors are starting to revisit large, diversified healthcare companies.
• In that context, Medtronic scores a 6 out of 6 valuation checks. The rest of this article will walk through what different valuation methods say about the stock, before finishing with a way to think about value that goes beyond any single model.

Approach 1: Medtronic Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to a single estimate of what those cash flows are worth in today’s dollars.

For Medtronic, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is reported at $5.44b. Based on analyst inputs for the early years and then extrapolated estimates after that, Simply Wall St projects Free Cash Flow reaching about $8.74b in 2035, with the path in between shaped by a mix of analyst forecasts and moderated growth assumptions.

Those future cash flows are discounted back to today using the model’s required return. This produces an estimated intrinsic value of $95.88 per share. Compared with the recent share price of $76.15, this implies Medtronic is trading at roughly a 20.6% discount to that DCF estimate. On this cash flow view, the model indicates the stock is undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Medtronic is undervalued by 20.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Medtronic Price vs Earnings

For a profitable company like Medtronic, the P/E ratio is a useful way to gauge how much you are paying for each dollar of earnings. Higher growth expectations and lower perceived risk usually support a higher “normal” P/E, while slower growth or higher risk tend to justify a lower one.

Medtronic currently trades on a P/E of 21.19x. That compares with an average P/E of 25.17x for the wider Medical Equipment industry and about 32.70x for peers, so the stock is priced below both of those benchmarks. On the surface, that might suggest a lower valuation than many similar companies.

Simply Wall St’s Fair Ratio offers another angle. It estimates what a suitable P/E might be for Medtronic given factors such as its earnings profile, industry, profit margins, market cap and risk characteristics. Because it is tailored to the company, the Fair Ratio of 27.52x can be more informative than a simple comparison with broad industry or peer averages.

When comparing the Fair Ratio of 27.52x with the current P/E of 21.19x, Medtronic’s stock appears to trade below the level suggested by this earnings multiple view.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Medtronic Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in, giving you a clear story behind the numbers you see for Medtronic such as fair value, revenue expectations, earnings and profit margins.

A Narrative is simply your view of the company written into a set of assumptions, so you connect the business story to a financial forecast and then to a fair value that you can compare directly with the current share price.

On Simply Wall St, Narratives sit inside the Community page as an easy tool used by millions of investors, helping you decide whether Medtronic looks attractively priced or stretched by lining up each Narrative fair value against the live market price.

Narratives also update when fresh information such as news, product announcements or earnings hits the platform, so your story and its fair value estimate are kept in line with the latest Medtronic data rather than going stale.

For example, one Medtronic Narrative on Simply Wall St currently estimates fair value at US$82.66 while another has a higher fair value of US$108.00, which shows how two investors looking at the same company can reach very different conclusions once they plug in their own revenue growth, margin and discount rate assumptions.

Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.